Deal will see the two US groups co-develop chips for PCs and data centres

Two men and a woman taken to London police station for questioning before being released on bail with conditions

Central bank concerned that deals are driving investment away from UK productive assets

Charlie Kirk’s deplorable murder has sent Republican hypocrisy on the subject rocketing

Tight competition

Bank dials back efforts to shrink balance sheet in bid to reduce impact on gilt market

Move could be followed by an initial listing in a year or two at a valuation of about $10bn

Ahmed al-Sharaa suggests talks may yield results in coming days

Consulting group revamps internal processes after condemnation for work on Palestinian relocation proposal

Sir Keir Starmer says agreement includes £150bn of investment in the UK

Despite a calamity in the 1980s, private investors are returning to the 300-year-old scheme

Chain says fewer jobs, stifling regulation, unsustainable government spending and higher taxes will take toll

Launch of Meta’s first model with a built-in screen marred by technical glitches

Plus, who gets to own a home?

Beijing regulator’s investigation had centred Android operating system’s dominance

It’s not hard to see how so many came to worry about the issue. But the data isn’t there

Bank has ‘no other realistic option but to leave’ to protect its competitiveness, says co-founder of investor

Pressure to repatriate Afghans is leading to increased official contact with isolated Islamist regime

US supermajors seek to emulate success of transatlantic peers such as Shell, BP and Total

Meredith Kopit Levien says newspaper will not back down after US president sues for $15bn

White House shifts from defending dissent to vowing crackdown on ‘hateful’ rhetoric in wake of killing

Late-night TV host’s remarks about the man accused of killing the conservative activist provoked criticism

But after spending time with the King, the US president may face a tricky final day as he holds talks with Keir Starmer

Danish drugmaker is racing to beat arch-rival Eli Lilly to market